Lilly forced to halt two prasugrel studies

Eli Lilly and Co. announced Wednesday its suspension of two small trials of prasugrel, a blood-thinning drug it developed with Daiichi Sankyo Co., due to dosage concerns. The company said the studies will remain suspended until their procedures are modified, but affirmed its plan to seek FDA approval for the drug by the end of the year.

View Full Article in:

Wall Street Journal (tiered subscription model), The · CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Fridley, MN
Product Patent Attorney
Foster City, CA
Employment Counsel
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC